Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported Q1 2026 consolidated revenue of KRW 1.26T and operating profit of KRW 580.8B, marking a year-over-year increase of 25.8% and 35.0%, respectively.
📊 [Key Disclosure Details & Financial Summary]
- Reporting Period:
- Current Period (Q1 2026): 2026-01-01 ~ 2026-03-31
- Previous Period (Q4 2025): 2025-10-01 ~ 2025-12-31
- Same Period Last Year (Q1 2025): 2025-01-01 ~ 2025-03-31
- Cumulative Current Period (Q1 2026 Cumulative): 2026-01-01 ~ 2026-03-31
- Cumulative Same Period Last Year (Q1 2025 Cumulative): 2025-01-01 ~ 2025-03-31
- Q1 2026 Preliminary Consolidated Performance:
- Revenue: KRW 1.26T / KRW 1,257,119M (-2.2% QoQ, +25.8% YoY)
- Operating Profit: KRW 580.8B / KRW 580,753M (+9.9% QoQ, +35.0% YoY)
- Profit Before Income Tax: KRW 640.6B / KRW 640,593M (+11.5% QoQ, +45.9% YoY)
- Net Profit: KRW 469.2B / KRW 469,245M (+3.6% QoQ, +41.6% YoY)
- Net Profit Attributable to Owners of Parent: KRW 469.2B / KRW 469,245M (+3.6% QoQ, +41.6% YoY)
- Other Key Notes:
- Figures are preliminary and subject to change depending on the external auditor’s audit results.
- Q4 2025 and Q1 2025 figures are based on audit reports prior to reflecting discontinued operations profit/loss from Samsung Bioepis due to corporate spin-off.
- Q1 2025 Samsung Bioepis discontinued operations profit/loss: KRW 44.22B
- Q4 2025 Samsung Bioepis discontinued operations profit/loss: KRW 56.90B (FY2025 cumulative KRW 170.02B)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of External Auditor’s Audit Results and Final Figures
These figures are preliminary results prepared prior to the completion of the external auditor’s audit. Checking the external auditor’s review or audit opinion and finalized financial statements in the upcoming periodic report is important for identifying any discrepancies between preliminary and finalized figures. Details can be verified in the financial statements and external auditor’s review report section of the upcoming quarterly report.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
